SCHEMBL13229587

SCHEMBL13229587

O=C(Nc1ccccc1)c1c[nH]c2ccsc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 12/20 0.63
CYP3A4 P08684 1/20 0.54
HTR3A P46098 1/20 0.54
MAOB P27338 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
GABRA1 P14867 1/20 0.44
GABRB1 P18505 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GABRB2 P47870 1/20 0.44
GABRA4 P48169 1/20 0.44
GABRA6 Q16445 1/20 0.44
ALDH1A1 P00352 1/20 0.43
DHODH Q02127 1/20 0.43
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13229634 0.83 CYP3A4 (0.48) CFTRCYP3A4HTR3AALDH1A1KDM4E
SCHEMBL13229624 0.82 CFTR (0.48) CFTRCYP3A4HTR3AMAOBMEN1
SCHEMBL6479523 0.81 POLB (0.56) CYP3A4HTR3AKMT2ANPC1RAB9A
SCHEMBL13229581 0.80 CYP3A4 (0.55) CFTRCYP3A4HTR3AKMT2ATDP1
SCHEMBL2793777 0.79 CYP3A4 (0.50) CYP3A4HTR3AMEN1KMT2AALDH1A1
SCHEMBL14780622 0.79 CFTR (0.65) CFTRCYP3A4HTR3AMAOBNPC1
SCHEMBL13229585 0.78 CFTR (0.63) CFTRMAOBMEN1KMT2ATDP1
SCHEMBL13229697 0.78 CYP3A4 (0.49) CFTRCYP3A4HTR3AMEN1KMT2A
SCHEMBL398391 0.77 CFTR (1.00) CFTRMAOBMEN1KMT2ANPC1
SCHEMBL13229620 0.77 CYP3A4 (0.47) CFTRCYP3A4HTR3AMAOBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170901-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2015-07-01 EP disclosed
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-21 US disclosed
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-05 US disclosed
US-8399479-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-19 US disclosed
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-01 US disclosed
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI CFTR, ABCB1, ABCC1 CFTR 1/4885CYP3A4 3757/4885HTR3A 4289/4885
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CFTR 1/4885CYP3A4 3621/4885HTR3A 3751/4885
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CFTR 1/4885CYP3A4 3621/4885HTR3A 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.